Literature DB >> 7482433

Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro.

R Knöfler1, T Nakano, K Nakajima, Y Takada, A Takada.   

Abstract

We have developed a simple, rapid assay method to measure remnant-like lipoproteins by using an immunoaffinity gel mixture of anti apo B-100 and apoA-1 antibodies to Sepharose 4B. Characterization of the unbound lipoproteins has shown that they represent chylomicron and VLDL remnant particles (RLP). Preincubation of whole blood with RLP resulted in the enhanced activation of aggregation with ADP and collagen. Such enhancement was not observed in the presence of lipoprotein deficient serum or albumin preparation. The extent of enhancement was 2.78 times by 7.5 microM of ADP and 44 times by 0.5 microgram/ml of collagen in the presence of RLP-preparation 1 (RLP-1), respectively. In the presence of RLP-2, the enhancement was 5.37 times by 7.5 microM of ADP and 102 times by 0.5 microgram/ml of collagen, respectively. On the other hand RLP slightly inhibited PRP aggregation by these agonists. Inhibitions were 19% by 7.5 microM of ADP and 18% by 1.0 microgram/of collagen in the presence of RLP-1, respectively. Incubation of whole blood with RLP did not result in the release of factors to stimulate platelets or ADP- or collagen-induced platelet aggregation in vitro. The extents of enhanced aggregation in whole blood or inhibition in PRP were not correlated with RLP-cholesterol nor RLP-protein concentrations of RLP preparations used. These results may indicate that RLP not only interact with platelets but with erythrocytes or leukocytes. Our findings support the hypothesis that the postprandial increase in remnant lipoproteins is an atherosclerotic risk factor and may be a part of the reasons of thrombotic complications by stimulating platelets in patients with remnant hyperlipoproteinemia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7482433     DOI: 10.1016/0049-3848(95)00044-5

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Postprandial lipoprotein metabolism: VLDL vs chylomicrons.

Authors:  Katsuyuki Nakajima; Takamitsu Nakano; Yoshiharu Tokita; Takeaki Nagamine; Akihiro Inazu; Junji Kobayashi; Hiroshi Mabuchi; Kimber L Stanhope; Peter J Havel; Mitsuyo Okazaki; Masumi Ai; Akira Tanaka
Journal:  Clin Chim Acta       Date:  2011-04-19       Impact factor: 3.786

2.  EPA, but not DHA, decreases mean platelet volume in normal subjects.

Authors:  Yongsoon Park; William Harris
Journal:  Lipids       Date:  2002-10       Impact factor: 1.880

3.  n-3 long-chain FA decrease serum levels of TG and remnant-like particle-cholesterol in humans.

Authors:  Kei Hamazaki; Miho Itomura; Mingming Huan; Hiroto Nishizawa; Shiro Watanabe; Tomohito Hamazaki; Shigeki Sawazaki; Katsutoshi Terasawa; Shuuji Nakajima; Takashi Terano; Yoshiya Hata; Seiichi Fujishiro
Journal:  Lipids       Date:  2003-04       Impact factor: 1.880

4.  Lipid Profiles in Out-of-Hospital Sudden Unexpected Death.

Authors:  Nisha Hosadurg; Brittany M Bogle; Golsa Joodi; Murrium I Sadaf; Irion Pursell; Philip M Mendys; John P Mounsey; Ross J Simpson
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2018-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.